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Abstract
Background: The goal of this study was to evaluate the effects of L-Dopa medication in Parkinson’s disease (PD) on brain
activation during the performance of a set-shifting task. Using fMRI, we have previously studied the patterns of activity
observed in patients with PD after overnight removal of dopaminergic medication compared with control participants
during the performance of different stages of the Wisconsin Card Sorting Task (WCST). The results revealed decreased
cortical activity in the PD group compared to controls in the conditions that significantly required striatum, while increased
cortical activity was observed when striatum was not involved. However, the effect of dopaminergic medication in PD
patients on those patterns of activity has not yet been studied.
Methodology/Principal Findings: Here, eleven PD patients at early stage of the disease taking L-Dopa medication were
recruited and underwent two fMRI sessions while performing the WCST: one session while taking their normal dose of
medication and the other following overnight dopaminergic medication withdrawal. We found that L-dopa medication
helped restoring a normal pattern of activity when matching and not planning was required, by increasing cortical activity
in the premotor cortex. This effect was even stronger in the motor loop, i.e. when the putamen was required for controls,
when matching following negative feedback. However, the medication did not change the pattern of activity in conditions
relying primarily on a cognitive loop, i.e. when the caudate nucleus was required.
Conclusions/Significance: These studies provide explanation at the neural level regarding the relatively poor effects of L-
Dopa on the cognitive deficits observed in PD.
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Introduction
Patients suffering from PD exhibit a specific array of motor
symptoms, but a wide range of non-motor deficits can also appear
in the course of the disease; including cognitive changes which can
lead to a full-blown dementia [1]. These cognitive impairments
resemble those observed in patients with frontal lesions [2], as PD
patients seem to be particularly impaired at tasks relying on
executive functions, such as the Wisconsin Card Sorting Task
(WCST) [3]. The origin of these impairments is still controversial.
Some authors have hypothesized them to originate from a
disruption of striatal outflow [4], itself caused by dopaminal
depletion and resulting in frontal dysfunction through the general
unbalance of the cortico-striatal loops [5]. Others have proposed
that they may result from an overactive dopaminergic tone in the
prefrontal cortex via the meso-cortical pathway [6,7]. We have
previously proposed that both may actually occur depending on
the striatal requirement for the task [8,9].
In a previous study with healthy subjects, we investigated the
functional contributions of distinct cortico-striatal circuits to
various stages of the WCST, using event related 1.5T fMRI
[10]. The ‘‘cognitive’’ fronto-striatal loop [5], including the
caudate nucleus and the prefrontal cortex (PFC) was activated
when planning a set shift, while the ‘‘motor’’ fronto-striatal loop,
including the putamen and the premotor cortex (PMC, areas 6, 8)
was found when executing a set-shift [10]. These results were
recently reproduced [11] using the 3T MRI scanner we used in
the present study. We used the same fMRI protocol in PD patients
OFF dopaminergic medication and matched controls to study the
effect of the disease on the aforementioned fronto-striatal networks
[8]. The premotor cortex of PD patients exhibited decreased
activity only when the putamen was required for the task in
controls, and in the ventrolateral prefrontal cortex (VLPFC) when
the caudate nucleus is required. On the other hand, increased
activation was found in various prefrontal regions in the PD
patients vs. controls for conditions not requiring the striatum. This
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functional level the cognitive impairments that progressively
appear in PD. However, the effect of L-Dopa medication on
these two loops remains poorly understood.
The most common treatment of PD is based on the
administration of L-Dopa. In the majority of PD patients, the
improvement of the motor symptoms is often spectacular. Little is
known, however, about the effect of L-Dopa on cognitive deficits
and studies have reported them to be eitherbeneficial [12] or
deleterious [13,14].
The goal of the present study was to assess whether, and to what
extent L-Dopa medication restores normal patterns of activation
in the cognitive and motor cortico-striatal loops that have been
identified respectively for the planning and the execution of set-
shifting processes in the WCST. Based on the striatal-dependent
patterns of activity we observed in PD OFF medication vs. controls
[8], we predicted L-Dopa to act significantly more on cortical
regions that co-activate with the striatum during the task (such as
the PMC when executing a set-shift) than on cortical regions that
do not. Furthermore we expected the effect to be more
pronounced for the periods of the task that relies on motor
networks (i.e. the matching periods) than cognitive ones (i.e. the
feedback periods).
Materials and Methods
Participants
11 patients diagnosed with Parkinson’s disease (mean age, 63.9
years; range: 55–78, 4 females and 7 males, 10 right handed and 2
ambidextrous) participated in the study (see table 1). All
participants met the core assessment program for surgical
interventional therapy criteria for the diagnosis of idiopathic PD
[15,16], namely two of the three cardinal signs of PD
(bradykinesia, tremor, rigidity), response to L-dopa, and lack of
evidence of other medical conditions associated with Parkinson-
ism. Motor disability of individuals within the PD group was in the
mild to moderate severity range according to the Hoehn and Yahr
staging criteria [17]. All patients were medicated with levodopa–
carbidopa (n=11), and were taking on average 523 mg of L-Dopa
per day. Some patients were also taking other antiparkinsonian
medications as follows: dopamine agonists/Pramipexole (n=4),
MAO-B inhibitor/Selegiline (n=2), COMT inhibitor (n=4). All
individuals were screened for dementia prior to the experiment
using the Montreal Cognitive Assessment [18] (mean average ON
25.4, OFF 26.2). The presence and severity of depression in all PD
participants was estimated using the Beck Depression Inventory
(BDI) (mean average ON 7.8, OFF 7.9).
Ethics statements. All participants gave informed consent to
the protocol, which was reviewed and approved by the Joint Ethics
Committee of the Regroupement Neuroimagerie Quebec, which
follows the guidelines of the Tri-Council Policy Statement of
Canada, the civil code of Quebec, the Declaration of Helsinki and
the code of Nuremberg.
Cognitive task. The same version of the WCST we have
used previously [8,10] was administered using a customized
software, and a full description of the task can be found in those
reports. Briefly, throughout the task, four fixed reference cards
were present in a row in the upper part of the screen, displaying a
red rectangle, two green stars, three yellow crosses and four blue
circles. Participants used a 2 buttons response-box with their right
hand (index and middle finger). The index button moved a cursor
along the four reference cards, and the middle finger confirmed
the choice. On each test trial, a new card was presented. Subjects
were required to match the test card to one of the reference card
according to the color, the shape or the number of items shared by
the test and reference cards. The rule for classification was not
explicit and had to be found using feedback (positive or negative)
that followed each trial. On each experimental trial, participants
had to find the proper classification rule and apply it as long as a
positive feedback followed the selection. A change in the screen
brightness reflected a correct (bright screen) or incorrect (dark
screen) answer. On each control trial, the test card was identical to
one of the four reference cards, and therefore participants only
had to select the twin reference card.
We defined six experimental time periods: three feedback
periods: negative, positive, or control feedback and three
corresponding matching periods i.e. matching after negative,
positive, or control feedback. Each feedback period lasts 2.30 s,
Table 1. subjects information.
Subj. gender age lat.
Years since
diagnosis
L-Dopa daily
intake (mg) Other anti-parkinsonian med.
Time since last
med. intake (h) UPDRS
comT
inhibitor
MAO-B
inhibitor
DA
agonist On Off
1 F 67 R 10 700 14 15 23
2F 5 5 R 1 3 7 0 0 N 12 19 34
3 F 59 R 5 300 13 16 25.5
4 F 56 R 5 150 NN 15 14.5 31.5
5 M 73 R 2 400 N 17 22.5 35
6 M 57 A 3 1200 N 12 25 29
7 M 66 R 2 550 12 13 24.5
8 M 67 R 8 450 NN 12 23.5 34
9 M 78 R 10 700 12 25.5 33.5
10 M 57 A 9 300 N 17 12 23
11 M 68 R 6 300 NN 15 25 32
Average 63.9 6.6 522.7 13.7 19.2 29.5
Abbreviations: Subj.: subject, F: female, M: male, lat.: laterality, R: right-handed, A: ambidextrous, med.: medication, DA: dopamine.
doi:10.1371/journal.pone.0006154.t001
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response time.
Activity in the appropriate period of the control trials was
subtracted from that of the different experimental event periods
for the color, shape, and number of items trials to generate the
following four contrasts for statistical analysis: (1) receiving
negative feedback minus control feedback; (2) matching after
negative feedback minus control matching; (3) receiving positive
feedback minus control feedback and (4) matching after positive
feedback minus control matching.
Procedure
All participants came for two scanning sessions within two
weeks, once OFF their prescribed antiparkinsonian medications
for at least 12 hours (‘‘OFF’’ state) and the other time ON their
usual medications (‘‘ON’’ state). ON and OFF sessions order was
counter-balanced across participants. Prior to each session,
participants were evaluated for their motor symptoms with the
UPDRS III (ON: 19.2 (sd 5.3), OFF:29.5 (sd 4.7), p,0.001).
All participants were trained on the task prior to each the
scanning session for at least 30 minutes and until no additional
improvement could be observed. Each scanning session consisted
in five functional runs. Within each run, blocks of each of the four
trial types (color, shape, number and control) were presented in
random order, so that no trial type could be repeated before all
four trial types had occurred. In the experimental WCST trials
blocks, six correct matching responses had to be completed in a
row before a rule change occurred. The control blocks contained
eight trials each.
fMRI scanning
Data acquisition. Subjects were scanned using the 3T
Siemens Trio MRI scanner at the Functional Neuroimaging
Unit, at the Research Center of the Montreal Geriatric’s Institute.
Each scanning session began with a T1-weighted volume
acquisition for anatomical localization (voxel size, 1 mm
3). This
was followed by acquisitions of echoplanar T2*-weighted images
with blood oxygenation level-dependent contrast (echo time,
30 msec; flip angle, 90u). 155 volumes containing 36 slices (matrix
size, 64664 pixels, voxel size 3.763.763.7 mm3) were acquired
continuously every 2.5 sec within each run. Stimulus presentation
and scanning were synchronized at the beginning of each run.
Data analysis. Data analysis were performed with the
fmristat software, developed by Worsley et al. [19] (http://www.
math.mcgill.ca/keith/fmristat/) similarly to our previous studies
[20] and was based on was based on a linear model with correlated
errors. The design matrix of the linear model was first convolved
with a difference of two gamma hemodynamic response functions
timed to coincide with the acquisition of each slice. The
significance of peaks is reported using the minimum p value of
the single peak analysis and cluster analysis. All peaks that reached
p,0.05 corrected are reported. Predicted peaks that reached
p,0.0001 uncorrected are also reported, and are shown with a *
in the tables. A region was predicted if it was significant in our
study using the same fMRI protocol on PD and healthy subjects
[8].
Results
Behavioural performance
Patients in their ON state completed an average of 25.7 (OFF:
29.7) experimental WCST trial blocks and 9.2 (OFF: 9.9) control
blocks during the five runs. They made on average 1.45 (OFF:
0.86) perseverative errors (i.e. errors attributable to the fact that
the subject incorrectly used the same classification rule after
negative feedback) and 0.78 (OFF: 1.00) non-perseverative errors
(loss of the rule) per WCST trial bloc. They made an average of
1.85 (OFF: 1.82) incorrect classifications per experimental WCST
trial block after a change in the rule – but the later were not
considered as errors because subjects could not know the new
classification rule on the first attempt after a set shift. None of these
behavioral differences reached significance between the ON and
OFF states.
fMRI results
As predicted, a significant effect of L-Dopa was only found in
the condition when a motor cortico-striatal loop was required for
the task at hand [8,10]. Indeed, significantly increased activity in
the ON vs. OFF state was observed during matching following
feedback vs. control matching, while no other significant activation
was observed in any of the other three subtractions in the ON vs.
OFF state. Below, both the results for the intra-group analysis (ON
and OFF separately), and the inter-group analysis (ON vs. OFF,
and OFF vs. ON) are reported for each of the four contrasts of
interest. It should be noted that the patterns of activation observed
in the present study during the OFF state were similar to those
observed in our previous study [8] using the same protocol in
another group of PD patients OFF with a 1.5T scanner. The
dorsolateral prefrontal cortex (DLPFC), the posterior PFC and the
anterior cingulate gyrus were observed during the reception of
negative feedback, and the DLPFC when matching following
negative feedback.
1) Receiving negative feedback vs. control feedback
ON state: (Table 2, Figure 1), we found significant activity
increases bilaterally in the prestriate cortex (area 19). There were
also increases of activity in the left hemisphere in the DLPFC (area
9,46), in the PMC (area 6) and in the right hemisphere, in the
anterior cingulate cortex (area 32). OFF state: only subtle
differences were notable, as there was no increase of activity in the
anterior cingulate cortex, but additional activity in the left
posterior parietal cortex (PPC, area 7). Intergroup compari-
son: we found no significant difference of activity.
2) Matching after negative feedback vs. control matching
ON state: (Table 3, Figure 2) we found significant activity
increases in the left hemisphere in the PMC and supplementary
motor area (area 6), in the inferior parietal cortex (area 40), the
prestriate cortex (area 19) and temporal cortex (area 39). There
were also bilateral increases in the superior parietal lobule and the
precuneus (area 7). OFF state: bilateral increase of activity was
more extended than in the ON state, in the bilateral prestriate
cortex (areas 17,18,19) and in the PPC (area 7). By contrast, we
found also significant increase of activity in the left DLPFC (area
9,46) but not in the left PMC (area 6) and temporal cortex (area
39). Intergroup comparison: the left PMC (area 6) was
significantly more activated in the ON than in the OFF state.
Conversely, prestriate cortex (area 18,19) was significantly more
activated in the OFF than in the ON state.
3) Receiving positive feedback vs. control feedback
ON state: (Table 4, Figure 3) we found significant activity
increase in the bilateral prestriate cortex (areas 17,18,19), in the left
superior parietal lobule, precuneus (area 7) and DLPFC (area 9) and
in the right rostral cingulated cortex (area 32). OFF state:
Significant activation were virtually the samein the prestriatecortex
and in the superior parietal lobule as in the ON state, but there were
L-Dopa and PD Neural Activity
PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6154Figure 1. Patterns of activation in the left VLPCF and right cingulated cortex when receiving negative feedback compared to
control feedback. A – appearance of the monitor when receiving negative feedback and control feedback. B – axial section (z=28 mm) in the ON
and OFF groups and in the intergroup analysis showing greater activations in the ON – OFF comparison.
doi:10.1371/journal.pone.0006154.g001
Table 2. Receiving negative feedback minus control feedback.
Anatomical area ON medication OFF medication
x, y, z t-stat Cluster x, y, z t-stat Cluster
Anterior CC (32) R 10, 34, 28 4.49 1016 10, 30, 30 4.09* 168
Posterior PFC (6,44) R 42, 14, 28 3.94* 336
PMC (6) L 244, 6, 40 3.69* 256
DLPFC (46) L 242, 28, 26 4.50 2496 240, 34, 14 4.01 3016
(9) L 242, 22, 38 4.09 sc
PPC (7) L 220, 278, 52 3.91 592
pcu (7) 2, 280, 42 3.99* 432
Prestriate cortex (17) L 26, 276, 8 4.84 .10000 26, 288, 4 4.71 .10000
(17) R 10, 266, 10 5.21 sc 18, 280, 6 4.20 sc
(18) L 216, 288, 14 3.70 sc 26, 266, 2 5.79 sc
(18) R 28, 274, 28 6.45 sc 26, 272, 26 5.16 sc
(19) L 216, 288, 24 3.65 sc 238, 284, 4 4.82 1808
(19) R 30, 278, 24 4.46 sc 36, 284, 4 4.97 2976
ON greater than OFF OFF greater than ON
- --- - -
Abbreviations: L, Left; R, right; DL, dorsolateral; VL, ventrolateral; CC, cingulate cortex; PMC, premotor cortex; PPC, posterior parietal cortex; TC, temporal cortex; pSMA,
presupplementay motor area. When no asterisk is indicated, p,0.05 corrected; *p,0.001 uncorrected. Cluster sizes are reported in mm3. sc indicates that the peak is
part of the same cluster as the peak listed immediately above in the table. The numbers in parentheses refer to architectonic areas.
doi:10.1371/journal.pone.0006154.t002
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comparison: we found no significant difference of activity
4) Matching after positive feedback vs. control matching
ON state: (Table 5, Figure 4), we found significant activity
increases in the left PMC (area 6) and in the medial PPC (area 7).
OFF state: increases of activity were found in the left PPC (area
7) and in the bilateral prestriate cortex (area 18,19). Intergroup
comparison: we found only a marginal increase of activity in the
left prestriate cortex when comparing the OFF to the ON state.
5) Matching after negative feedback vs. matching after
positive feedback
We computed that additional contrast to specifically assess the
effect of L-Dopa on the left PMC, which was found in ON
contrasts (2) and (4) (Table 6). Significant activation was found in
the left premotor area in the ON but not in the OFF state. The
intergroup comparison did not show increase of activity in the left
premotor cortex.
Discussion
The goal of the present study was to assess the extent to which
L-Dopa medication restores normal patterns of activation in the
cognitive and motor cortico-striatal loops in the context of WCST
set-shifting. We expected L-Dopa to help restore the patterns of
activation observed in controls [10], only when the putamen was
required, i.e. during set-shifts.
The key findings of this study in relation to our hypothesis is
that, as predicted, L-Dopa medication restored the function of the
motor cortico-striatal loop, during the execution of a set-shift since
significantly more activation was found in the PMC during the
ON vs. the OFF state when matching after negative feedback was
compared with control matching (Figure 5). While an increase in
activity was also observed in the PMC in the ON vs. the OFF
state, when matching following positive feedback vs. control
matching, the effect was not as large. Indeed, it was also found
significantly more activated in the ON state only when comparing
directly ‘‘matching after negative feedback’’ with ‘‘matching after
positive feedback’’. The ‘‘matching after negative feedback’’
condition was shown to rely on the motor cortico-striatal loop
and, unlike ‘‘matching after positive feedback’’, required putam-
inal activation in young healthy adults [10] (Figure 5). The
computation of an additional contrast, namely ‘‘matching after
negative feedback vs. matching after positive feedback’’, revealed
an activation of the left PMC in the ON and not in the OFF state
establishes that L-Dopa medication had a stronger effect when the
putamen was required by the task than when it was not.
By contrast, the medication did not restore the cognitive loop
activity observed in controls when planning the set-shift. The
‘‘receiving negative feedback’’ condition was shown to rely on the
cognitive loop [10] (including caudate nucleus and VLPFC,
Figure 5). This result could be explained by the fact that the
participants were at an early stage of the disease and exhibited
signs of mild cognitive impairments at the maximum, but no signs
of dementia, as assessed by the MoCA test. This suggests that the
level of dopamine in the caudate nucleus may not have reached a
functionally disabling threshold in the patients studied here, which
explains the similar behavioral results between the ON and OFF
states. Furthermore, the current results showed that L-Dopa
Table 3. Matching after negative feedback minus control matching.
Anatomical area ON medication OFF medication
x, y, z t-stat Cluster x, y, z t-stat Cluster
PMC (6) L 224, 8, 66 5.96 4464
pSMA (6) 0, 16, 56 4.39 1568
DLPFC (46) L 250, 30, 26 4,40 3416
(9) L 240, 26, 34 4,32 sc
PPC (7) L 214, 272, 48 4.24* 288 232, 272, 52 5,32 .10000
(7) R 22, 270, 58 4.32 528 30, 274, 54 4,02 2560
(40) L 238, 256, 46 5.66 .10000
pcu (7) L 22, 268, 58 4.74 8240 22, 272, 66 4,02 2560
(7) R 8, 270, 58 4.37 sc 6, 274, 56 3,90 sc
TC (39) L 254, 266, 214 4.59 5128
Prestriate
cortex
(19) L 226, 268, 40 4.77 8240 228, 276, 36 5,33 .10000
(19) R 30, 284, 26 4,93 1568
(18) L 224, 294, 214 4,18 .10000
(18) R 28, 282, 216 5,50 sc
ON greater than OFF OFF greater than ON
PMC (6) L 222, 6, 66 3.85 224
Prestriate
cortex
(18) R 26, 290, 216 4,12 1032
(19) L 244, 286, 210 3,84* 280
Abbreviations, same as Table 2.
doi:10.1371/journal.pone.0006154.t003
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no significant activation was found in this region for any of the
experimental contrast in either of the two states (ON and OFF).
These observations are in line with previous FDG-PET studies
showing that unlike the PD-related motor pattern (PDRP), the
PD-related cognitive pattern (PDCP) expression was not signifi-
cantly altered by antiparkinsonian treatment with either intrave-
nous L-Dopa or deep brain stimulation [21]. In these studies,
network analysis in non-demented PD patients identified a spatial
covariance pattern associated with cognitive function and
significant correlations between this PDCP expression and
performance on tests of memory and executive functioning.
However, antiparkinsonian treatment failed to detect significant
changes in PDCP expression despite concurrent improvement in
motor ratings and reductions in abnormal PDRP activity.
Additionally, levodopa treatment has been shown to induce a
flow-metabolism dissociation (reduction of the cerebral metabolic
rate for glucose and rise of cerebral blood flow) in the PDRP,
especially in the putamen [22]. These findings might provide a
physiological basis for the BOLD contrasts reported in the present
study.
The lack of difference in performance on the WCST in this
study may appear to contradict reports that have suggested that
the cognitive profile of patients in the ON-state is improved
compared with the OFF-state [28]. However, it has been reported
that the effect of L-dopa on cognitive performance in PD patients
can be both positive and negative depending on the patient or the
task to be performed [29]. Most importantly, at least two prior
studies have reported that L-Dopa does not change performance
on the WCST in PD patients [28,30].
We have previously observed cortical over-activity in PD vs.
controls in conditions not significantly requiring striatum (i.e.
matching after and receiving positive feedback) in controls [8,9],
and had proposed it may be due to a mesocortical dopamine
deficiency. Other studies have reported that L-Dopa can help
reduce this cortical over-activity at least in the DLPFC [26,27].
However, such a pattern was not clearly observed in the present
study. The effect of L-Dopa on the DLPFC activation varied with
the specific task period that was performed, and overall L-Dopa
had little effect on cortical regions that did not co-activate with the
striatum for the task, which in turn implies that it did not
significantly alter mesocortical dopamine function. Another
interpretation of the cortical over-activity observed in PD
compared with control subjects is that it reflects a possible
compensatory effect [25], which would help explain why patients
at the early stages of the disease such as those in the present study
do not yet show significant cognitive impairments. This interpre-
tation is supported by the presence of significant activation
observed in the DLPFC in the patients OFF and not ON
medication when matching after negative feedback. In the OFF
state this DLPFC activation could reflect a compensation for the
lack of required PMC involvement, while in the ON state this
compensation is not required since the activation in PMC is
restored.
Our findings may reflect the fact that at early stages of the
disease, motor loop DA is depleted across all PD patients, as they
Figure 2. Patterns of activation in the left PMC when matching after negative feedback compared to matching in the control
condition. A – appearance of the monitor when matching after negative feedback and matching in the control condition. B – coronal section
(y=8 mm) in the ON and OFF groups and in the intergroup analysis showing greater activations in the ON – OFF comparison.
doi:10.1371/journal.pone.0006154.g002
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symptoms. The absence of enhanced cortical activity in the
cognitive loop may reflect the fact that L-Dopa intake was tuned to
the patients’ motor symptoms and not cognitive symptoms. Rowe
et al. [23] have proposed that L-Dopa medication can enhance or
restore striatal functions while impairing frontal functions by
Figure 3. Patterns of activation in the right cingulate cortex when receiving positive feedback compared to control feedback. A–
appearance of the monitor when receiving positive feedback and control feedback. B – axial section (z=28 mm) in the ON and OFF groups and in the
intergroup analysis showing greater activations in the ON – OFF comparison.
doi:10.1371/journal.pone.0006154.g003
Table 4. Receiving positive feedback minus control feedback.
Anatomical area ON medication OFF medication
x, y, z t-stat Cluster x, y, z t-stat Cluster
Anterior CC (32) R 8, 40, 30 4.00 456
DLPFC (9) L 244, 8, 38 3.93* 416
SPL (7) pcu 0, 282, 44 3.86 .10000
(7) R 12, 288, 48 4.55 .10000
Prestriate cortex (17) L 26, 292, 8 5.06 sc 24, 286, 4 4.36 sc
(17) R 14, 296, 2 3.99 sc 6, 286, 8 5.92 sc
(18) L 6, 282, 4 6.55 sc 6, 268, 0 5.12 sc
(18) R 26, 276, 8 5.66 sc 4, 274, 0 4.22 sc
(19) L 26, 290, 30 4.08 sc 216, 256, 0 3.80 sc
(19) R 12, 290, 28 4.81 sc
ON greater than OFF Off greater than ON
- ---- -
Abbreviations, same as Table 2.
doi:10.1371/journal.pone.0006154.t004
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comes from the small population sample and the fact that some
patients were prescribed different types of dopaminergic medica-
tion together with L-Dopa. Our results and conclusions could be
extended with a larger sample, as we could correlate, in the motor
and cognitive loops, the extent of activation gain provided by the
L-Dopa medication to the onset of the disease.
In conclusion, our study shows the functional implications of
the stronger dopamine depletion in the putamen than in the
caudate nucleus that is thought to occur in the early stages of
PD [24]. More specifically, L-Dopa has a significant effect on
the cortico-putaminal (motor) loop and not on the cortico-
caudatal (cognitive) loop. These results help explaining why L-
Dopa therapy is more effective in controlling motor symptoms
Figure 4. Patterns of activation in the left PMC when matching after positive feedback compared to matching in the control
condition. A – appearance of the monitor when matching after positive feedback and matching in the control condition. B – coronal section
(y=212 mm) in the ON and OFF groups and in the intergroup analysis showing greater activations in the ON – OFF comparison.
doi:10.1371/journal.pone.0006154.g004
Table 5. Matching after positive feedback minus control matching.
Anatomical area ON medication OFF medication
x, y, z t-stat Cluster x, y, z t-stat Cluster
PMC (6) L 224, 10, 68 4.99 2480
210, 212, 74 4.14 sc
PPC (7) 0, 254, 64 4.00* 368
(7) L 226, 266, 58 5.13 840
Prestriate cortex (18/19) L 218, 292, 16 4.25 576
(18/19) R 30, 284, 26 4.14 496
ON greater than OFF OFF greater than ON
PMC (6) L 28, 212, 78 3.61* 104
Prestriate cortex (18/19) L 244, 286, 2 3.87* 440
Abbreviations, same as Table 2.
doi:10.1371/journal.pone.0006154.t005
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PLoS ONE | www.plosone.org 8 July 2009 | Volume 4 | Issue 7 | e6154than cognitive deficits. In the future, this type of fMRI protocol
will allow for studies focusing on the effect of medication directly
oriented at cognitive deficits in PD, in order to develop different
treatment strategies.
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Table 6. Matching after negative feedback minus matching after positive feedback (partial).
Anatomical area ON medication OFF medication
x, y, z t-stat Cluster x, y, z t-stat Cluster
PMC (6) L 226, 12, 66 4.26 888 - - -
ON greater than OFF OFF greater than ON
- - --- -
Abbreviations, same as Table 2. We only report here the left premotor cluster of activation.
doi:10.1371/journal.pone.0006154.t006
Figure 5. Explanatory diagram of the major results of the present study. A, In healthy controls (left) a cognitive cortico-striatal loop
including the VLPFC and the caudate nucleus is significanty solicited when receiving negative feedback [10]. This activity is significantly reducedi n
PD patients OFF medication [8] and L-Dopa does not help restore the pattern of activation observed in control. B. In healthy controls (left), a motor
cortico-striatal loop including the PMC and the putamen is significantly solicited when matching after negative feedback [10]. This activity is
significantly reduced in PD patients OFF medication [8], and L-Dopa significantly restores the PMC activity (green circle) but not the putamen one. C.
In healthy controls (left), the PMC is significantly activated without the putamen when matching after positive feedback [10]. This activity is
significantly reduced in PD patients OFF medication [8], and L-Dopa partially restores the PMC activity (yellow dashed circle).
doi:10.1371/journal.pone.0006154.g005
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